Changes in patients’ financial burden after Pralsetinib is covered by medical insurance

Pralsetinib (Pralsetinib), as a targeted therapy for RET fusion-positive non-small cell lung cancer and other diseases, has been marketed in China, but has not yet been included in medical insurance. At present, the common specifications are 100mg Overseas original medicines are more expensive, with 60 tablets priced between 40,000 to more than 100,000 yuan. Although Laos has launched generic drugs, and the price of 120 tablets is more than 3,000 yuan, you need to bear the cost and risk of cross-border drug purchase.

If platinib is included in medical insurance and through national negotiations, the price of the drug is expected to be significantly reduced, usually to about 30% of the original price. After medical insurance reimburses the patient, the actual out-of-pocket portion may be reduced from tens of thousands of yuan to several thousand yuan or even lower. Such changes are of great significance to patients who have been taking medicine for a long time, and will effectively reduce the financial burden on families and improve the accessibility of medicines.

Targeted therapy usually requires long-term, regular medication, and the high cost often leads some patients to discontinue medication or reduce dosage. After being reimbursed by medical insurance, patients are more likely to adhere to standard treatment, which helps improve the efficacy and prolong survival. At the same time, it will also encourage more clinicians to recommend platinib and expand its clinical application population.

There are differences in medical insurance reimbursement ratios and policies in different regions, and some patients still need to pay a certain proportion out of pocket. It is recommended that patients take the initiative to consult the local medical insurance department after Platinib is included in medical insurance to understand the scope of reimbursement, process and required materials, and reasonably plan treatment expenditures. Overall, medical insurance coverage will significantly reduce the financial burden and bring more treatment opportunities and hope to patients.

Reference materials:https://www.drugs.com/